Latest / Powering the Future Within / Episode 10: Redefining What's Possible in Medical Imaging and Cancer Treatment
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of med tech. I'm Omari Bachnit, CEO of ResidentLink Medical. Each episode, we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today's guest is Gabriel Sanchez, founder and CEO of InSpektra Health. Gabriel is building one of the most ambitious imaging platforms in modern medicine. InSpektra is pioneering high resolution optical imaging designed to visualize tissue biology in real time at the point of care. Not just pictures, not just diagnostics, but dynamic cellular level insight that can change how clinicians make decisions. Gabriel has built his career turning deep technical innovation into practical clinical insight, and I'm excited to have him on the show. Gabriel, welcome to Powering the Future Within. speaker-1: Thanks for having me, Amari. Pleasure to be here. speaker-0: Absolutely. So at an early age, would you have predicted that you would find yourself working and leading in med tech? speaker-1: No, so that's a loaded question. Not in a million years. It's funny we say that. I guess for me it was 30 years, but whatever. No, would not have thought about that if you, those few folks that know about my background. So I grew up very rural, very agrarian. So I grew up on a cattle ranch and ⁓ a farm and I was in the fields and I did a lot of work in the fields and sort of my cultural experience and growing up was of... Sort of that environment. You know, if I would have thought of like innovation and technology or a company, I would have thought of like giant fortune 500 companies. You know, you think of like Chevron or small mom and pop shops, know, like little local town community companies. I never would have thought that it was possible to build a startup around an idea, to build a team around that, to potentially bring that out into the world. as a small company and to be able to really push, you know, a device of your own invention. You know, I grew up in a ⁓ New Mexico, which is a beautiful place. ⁓ I love the place. I love the pace of it, but it is a little bit parochial in terms of, ⁓ it is kind of a small town and a little bit of not a ton of innovation and maybe thinking at a bold level. if you were a kid, In that environment and you were like, ⁓ I'm going to start a company someday. It would almost be almost rude, almost too ambitious and too audacious to think that you could pull off something like that. Whereas I feel like, you where I live now in Silicon Valley, every single high school student is working on, you know, their next startup is completely normal. But, you know, it was, it's an interesting world in some ways, ⁓ gave me the space to sort of think and develop. You know, I lived very far from school. you know, 65 miles from my high schools. People always ask me like, did you drive that? And I'm like, yeah, of course. Like, I don't know how else you'd get there both ways. And it's like, yeah, I wanted to go home. But I had space to think and I had space to create. And I did have very supportive parents that were very motivated about education and interest, you know, coming from a relatively big family, two older sisters. three younger brothers, we probably have about 10 college degrees amongst us. you know, we all went heavily into education and really pursued that. And unfortunately, that means that we did largely move out of the family business of the farming and the ranching. And that is something that I think is unfortunately a little bit systemic in those communities across the country. yeah, moved us, you know, and allowed me to pursue my passions. And I was always... I was always deep in this area of science and technology and engineering, but I grew into it. I didn't really have a template to look at, I would say, in terms of examples or role models to follow to think about that. I just kept constantly kind of pursuing the next step that was interesting to me in my areas of interest and passion. it just evolved. And we'll probably get to this, but going through. Going through school, getting into research, getting increasingly into lab work, going into grad school, and then it just, you know, snowballed. So no, that long answer to your short question. speaker-0: So, I mean, that's a great point in terms of if you don't have a template, you don't really know that it exists. Can you recall what maybe some of your first templates were around innovation that would have exposed you to applying technical sciences to the world of entrepreneurship? that at university or did you discover a template even before that? speaker-1: It was mostly at university. There was a little bit earlier than that, I did get some deep involvement in sort of the local science fair community. I had, ⁓ without even knowing this, I actually had built a ⁓ prosthetic arm for my eighth grade science project, which now we would call medical device, but I just thought it was, I was very interested in robotics and. building physical systems and kind of one at the local level got to go into the sort of the city and then regional levels and got, got fairly far, went to the sort of the state level. ⁓ through that experience, you know, those science fairs were often held at the, at the local universities and, know, so like university of New Mexico, New Mexico tech. And so got some exposure to, ⁓ to some of that environment and started to realize that that was an interesting, ⁓ That was a very interesting environment for growing innovation and growing yourself academically. so I had a, that was maybe my earliest exposure to something a little bit in that direction. But honestly, when, you know, when I went to school and into this technical direction, most of this was just figuring this out one step at a time. ⁓ fortunately was a good student. So I went to MIT for undergrad. I was a good student. actually caught the attention of some of the researchers that were looking for undergrad students. basically went to ⁓ one of the early mechanical engineering professors and said, you who are your top two or three consistent performing students? We're looking for some folks to dive into research. And I was on that list. And so I got connected ⁓ actually in my freshman year of undergrad to a lab that was doing research and started to work in that space and realized started realize at that point that I did have lot of interest in doing some deeper scientific research. then that led me, although that project ended up not being something I was particularly interested in, it got me in the door, ⁓ started to meet with some other professors, see some other labs. And then where I think I really got hooked, I got connected into a lab, ⁓ Professor Ian Hunter's group that was focused on bioinstrumentation. And this was like right at the crossroads of hardcore technology, ⁓ electrical engineering, mechanical engineering, photonics, ⁓ and biology with applications to the human body and health. which is really like basically that was like that's med tech, was wearables, it was, you know, what we think of now. And that really got me hooked. And he was probably the first person, ⁓ he was also my undergrad advisor. And I had a meeting with him and he was like, you should really go for a PhD. I think you could do it. ⁓ It's like, you shouldn't really stop at the masters. think you're deeper than that. And he kind of, he kind of goaded me into it a little bit and, and sort of motivated me and I had that little fire under me. And so when I went to, ⁓ apply to grad schools, I had now, I, in some ways I just said this, like somebody was like, you should get a PhD. So I just had this idea. I should get a PhD. I had never met anyone with a PhD or, or, you know, met a professor other than, know, through my experience at school, but, ⁓ Went to Stanford for grad school and then just continued through that research approach. know, joined a lab right away, started doing research, started to meet with PhD and postdoc students and start to untangle and understand a little bit the process of how you would go there. But for me, I'm always just like, I just one step ahead at most, know, just trying to figure it out ⁓ and enjoying the ride. speaker-0: Yeah. And it strikes me that you, you arrive at Stanford and obviously a big experience there is being surrounded by innovation engine and likely a lot of people who have started and launched companies. almost feels like there must be something in the water around Stanford that makes people want to start companies. But did you at that point already see yourself applying engineering to medicine? It sounds like some of the other experiences you had previously had kind of tuned you in on applying. technology and engineering to medicine and health. speaker-1: I was starting to trend hard in that direction. But I was coming from a, my core interests, like I had said, even with my eighth grade science for a project, I was very interested in robotics and sort of space travel and ⁓ even space exploration and technology. I was getting there. ⁓ What I would say was consistent across my experience was actually, like I said, what happened with the undergrad was I tend to be a pretty strong performer. I was a decent communicator. would sort of meet people and sort of rub them in a way where they're like, ⁓ you know, this guy's like, like can do things. And then I would get, ⁓ get into some of these opportunities and a very similar thing happened at Stanford. So when I wrote, when I got to Stanford and my focus was, I've always been focused on broadening my, my kind of deep. skill set and expertise. And so I wanted to get deeper in mechatronics, learn more about electronics, computer programming, image processing. So I was sort of on that pathway. ⁓ But there was this relatively new program called Biodesign, Stanford Biodesign, and they were about three or four years into it. And they had started for the first time what they were kind of calling, I think, the continuation year or the second year where some of the program, some of the projects would maybe continue and pursue to see if some of their the needs that they had explored were worth pursuing and in a deeper ⁓ Sort of project and so this email went out to the entire mechanical engineering department From ⁓ from Paul Yaw's office from from Stanford biodesign where they said hey we have some continuing Fellows are basically clinical. They're clinicians. They have clinician backgrounds. They've identified needs that they think are interesting And we're looking for students that would like to participate in bench prototyping, some early work, some design, and potentially ⁓ work on how we might translate these technologies out into the next phase. And you could get college credit for it. You could basically get course credit for it. I applied. I was like, okay, so I wrote back and I sent an email in. They did a full formal interview process. It was very interesting. Apparently they interviewed a bunch of candidates. ⁓ What I found out later was I actually bought, I brought a portfolio. I brought a ⁓ box of prototypes and things that I had built and things that I had designed plus ideas that I was working on. so both kind of on paper and in physical form. And they were like, yeah, you're the only person who brought anything like in. So we were like, let's go with this guy. And ⁓ that got me working with Carlos, Mary and Bilal Shafi and they were working ⁓ on a congestive heart failure. project trying to build a like a resorbable restraint for the heart to kind of prevent it from dilating working on a lot of like bench work and delivery devices and that for me was that that was probably the main gateway that was the gateway that that really drove me in that direction because that was the first time I had seen a you know a clinical innovator who identified a problem started to crystallize an idea around how to how to approach that problem systematically, build a solution and then try to get it out. And then, and that was the, that was the first real world demonstration of that formula that I had seen. After that, after working with them for, for a few months, I started taking specifically some med device courses at Stanford, increasingly looking to work and do research in labs that were, that were working on kind of health related or health adjacent work. So I started working in the neuromuscular biomechanics lab, which was co-run across bioengineering and mechanical engineering by my advisor, Scott Delp. So it was a mix of kind of deep science and software and hardware, but focused on human movement and everything in human movement from elite athletes to severe neurological diseases and disorders. And that was also a very fertile environment for me to sort of continue and explore in this direction. And ultimately where I invented the technology that became InSpektra Health. it was, ⁓ Stanford does have something in the water and it might just be the Silicon Valley ⁓ environment. ⁓ Everybody's starting to company all the time, but it's hard not to get exposed to that, honestly, if you're in that environment because there's just so much of that activity happening. I kind of got hooked. speaker-0: Well, it's interesting that you showed up to the biodesign with concepts and prototypes, it sounds like InSpecual wasn't necessarily one of those, but it starts the process. And it also strikes me that part of the strength of the biodesign curriculum is really pushing the entrepreneur or the technologist to really focus on unmet need, which a lot of times as technicians or as engineers, The focus is on the cool technology, how neat the technology can be. Did you find that directionality in terms of pushing to focus on unmet need to be something that served you well going forward? speaker-1: Absolutely. And you know, in some ways that is a little bit of a contrast in the cultures between maybe MIT and Stanford. So I would say MIT is a little more tech push. ⁓ Innovation on, purest innovation on principle. We want to invent and innovate to elevate the world of knowledge and science. doesn't necessarily have to be commercially like blockbuster applications. ⁓ Stanford, in my experience, is a little more industrially focused, maybe ⁓ industry focused and ⁓ kind of driven by that Silicon Valley mindset. know, bio design kind of pulls all that together because you do have to, at the end of the day, have a commercially viable opportunity if you want anything to make an impact, right? So this is where, you know, getting exposed to this process, which is a systematic bio design process of identifying a need and then that need having All the attributes that you would want around it to make it hopefully fundable and fundable through the duration of the multiple milestones and kind of hurdles that you're to have to pass to get this to patients. But that that would be commercially exciting enough that you can, you can attract that investment and then bring it to the end. And I think that's a, that's a very critical and important discipline. think that, ⁓ people generally probably don't understand how difficult it is to get a a medical technology or a medical innovation or solution or therapy or diagnostic through the process. It's almost impossible. mean, you have to, it almost has to be borderline like malpractice that you wouldn't do it, right? Because it's so difficult and there's some good reasons, some bad reasons, some good reasons for that is that we need to be safe and systematic and we need to build strong evidence and to be able to demonstrate safety and effectiveness. Some of it is just the sheer complexity of the process. mean, you know, we always talk about the, you know, the person that, that experiences is the device, the patient is not the person who operates it. not the person who pays for it, not the person who regulates it, not the person who, you know, ultimately makes the decision about how to use it in the, in the hospital environment. So that fragmented structure, you have so many stakeholders that you have to build kind of cohesive alignment around it's, it's very difficult to do. So, so. Unlike ⁓ a consumer product where people want it. That's great. That's the, know, people want things and you can make a cool business. Like you have to need it in medicine because it's only if it's truly necessary that you could at least have enough motivation and dedicated resources to make this have a chance. Even then you still only have chance. ⁓ I think it's, ⁓ it would, it would surprise, it surprises. think even the people that want to get into it, even myself being close to it. learning it academically in the school environment, sort of experience it adjacently through ⁓ those bio design fellows that I was working with, completely different when I dove in head first and did it myself. ⁓ It ⁓ is brutal. ⁓ so it needs to be needed. The need is essential. Like it has to be necessary, otherwise it's... people want it, you know, it's just not, it's probably not going to happen. So it's a, yeah, it is a very important process. Absolutely. speaker-0: Yeah, it's a really interesting perspective. It's almost the difference between going to a place to visit versus actually living there from the outside. And kind of appreciate what the dynamics are. But when you're living and breathing it, it gives a whole different feel. the fact that, know, had been at MIT, you're at Stanford, surrounded by innovation, you've seen success stories, you have access to great resources like bio design and other coursework. And still it's really poignant how challenging the process can be that really, really says something. And to your point, what it all comes down to is then it must really be needed in the market for it to have a chance to get. speaker-1: Absolutely, it has to be necessary. that's the purest approach. Now, the funny thing is what we do at InSpektra, we play with the formula too, right? So, I think there's a difference between, yeah, like visiting or seeing it from the outside versus living there and being in the thick of it. And when you're learning the process and you're developing need statements and you're kind of going through the discipline of the biodesign process, and I've talked about this before, where that's a very deductive process. It's a funneling down. process that gets increasingly specific and it seems very formulaic. But I think when you live in it, what you realize is that it is cyclical. It's also very much, there's a lot of inductive reasoning where you branch out and you sort of dream and sort of brainstorm to like, are the unspoken needs and what are the ⁓ unappreciated sort of blind spots that people have. And so when you're in it in real life, yeah, you kind of have to play around and play in different ways. And, know, that was something that was really big at InSpektra. ⁓ Because sometimes if you ask on the surface, may not, if you're just interviewing people, they may not actually articulate or ask for the thing that they do need because they don't know that it could be addressed. And something like what we work on is very much in that realm because patients go to the dermatologist, they do what the dermatologist says they should do. And the dermatologists are doing good medicine. I'm not saying they're not, but they're going to take a biopsy and they're going to cut your skin and there's no alternative. You wouldn't know to ask for the help for an alternative. And if you're just grateful that they're scanning your skin and they're identifying skin cancers, you're not going to complain about it. But if, if suddenly there was an alternative where you're like, Oh, I could potentially get image noninvasively. could get screened earlier. I could get, you know, looked at more frequently, maybe not, maybe not have to wait five months to see a dermatologist. When you, if you lived in that context. Yeah, actually I do see some benefits, you know, and you might start to think about this a little differently. And that's where, you know, we think about some of these like latent sort of unspoken needs that are probably hidden beneath the surface that people couldn't really ask for. know, like historically we've seen those examples in things like personal computers and the internet and smartphones. It's, ⁓ you know, Henry Ford talked about the car where, you know, people would want a faster horse, right? I mean, Those are those blind spots that if you ask in the context of the present, sometimes limit ⁓ the information that you can gather. And so you do want to sort of broaden out inductively, look a little bit and say like, what if, and ⁓ we do that all the time at InSpectra. So I think you want to learn the process. And it's the way I think about all disciplines in my academic career is I want to learn down to base fundamentals, understand the pure process of whatever that particular topic is. And then now that you understand it, get creative. You know, that's like, what are we trying to little differently? What if we played with it a little different way? What if we looked in a different direction? ⁓ Find some of those hidden nuggets, you know, of real value. that is a little bit what we're doing at InSpektra because ⁓ we're just introducing something that has been... completely ignored for 150 years because we have always cut tissue out of the body to look at it histologically. And so we don't even think about an alternative to that. speaker-0: Yeah, I mean, what you're talking about essentially is redefining the standard of care. And redefine something that has been the standard for so long takes an extraordinary amount of effort and commitment. And we love to talk about disruptive technologies, but sometimes there's an under appreciation for what disruption means in terms of dedication to actually push it and pull it all the way through. So you started to get into the potential application of InSpektra. I would love to talk a little bit about the InSpektra origin story. this point, you've been exposed to a lot of different technologies. You've kind of gotten through the process of uncovering unmet needs. You've been exposed to a lot from an academic and science perspective. But what's the origin story of InSpektra? Where did it all start? speaker-1: So it's been a long journey. ⁓ It traces back to studying muscle disease, which seems a bit abnormal. But I was gung-ho on pursuing a PhD, and I had joined a lab, like neuromuscular biomechanics lab. So it's focused on human movement and muscle disease. Sometimes what you'll find across disciplines, though, is everyone's suffering from the same fundamental problems. So this was a lab that was building ⁓ complex advanced computer simulations of human movement. And it was actually like pre-AI days and now it's become, it has become AI, but it was in sort of more traditional ⁓ physics based models in the past. And so you had to feed those models with assumptions. And so you ⁓ would have experimental data that you would try to build these models around in terms of how muscles behave. Muscles have weird behavior when they change length and... And depending on the rates at which they change and how much ⁓ tendon do you have in line with the muscle and all of this affects the mechanical properties. And we had lots of good in vivo evidence, probably down to sort of the organ level of a muscle, which is sort of, let's say muscle and tendon. But if you want to go deeper dive into that, you want to understand how the cells of the muscle work. The muscle cell, is called a, ⁓ the structure within the cell that makes it contract is called a sarcomere. And it. embodies all the behaviors that you actually see at a macro level of the muscle. It's like a Lego and it's like you built the muscle out of this and it has these interesting force length property characteristics. We've known that certainly. We understood that there was this relationship, but we had no in vivo measurements of it because they're buried deep in the body and they are microscopic in scale. So there was this like dream of like, what if you could get in vivo sarcomere data. in a human body, you might actually be able to really refine these models and get better performance. And I started, I looked at that and I saw that fundamentally as a mechanical problem. There was ⁓ a ⁓ PhD student working on this right before I got there, Mike Llewellyn and Melinda Cromie, and they were basically using a technology called a multi-photon microscopy. So it's a microscope that scans a laser into tissue. two photons get absorbed, one photon gets emitted, and you can image biologic tissues this way. And a subset of that is called second harmonic generation, which particularly highlights collagen and myosin, which is the building block of muscle. So you can image muscle, but the problem is these devices are massive. They're 500 pound systems on big air tables. They're extremely finicky and complex to align and to maintain. ⁓ there was work on basically packaging some lenses into a micro-endoscope, so a needle the size of a flu gauge that you could stick into a muscle. But then you'd have to kind of align this under this two-photon microscope in 3D space with very high precision. And the only way you could kind of do this was to literally strap a person down on a gurney and then freeze the microscope and then just hope, you know, basically take a ton of pictures and hope at one point you finally got one that was usable. And when I looked at that, I felt that that was the bottleneck. said, we just don't, we're physically putting the human under the microscope as a sample, you know, and like, what if we could decouple this a little bit and bring a microscope to the body? You could even change posture locations and get different data. And so I, I proposed basically as a, as a project to my, my advisor, said, what if, what if I built a portable microscope that we could get in vivo ⁓ muscle data with? that's not a typical PhD project of typical PhD projects are not built around. technology innovation, but we both agreed that this would actually be very hard to do. And because of the degree of hardness, we're like, it might actually cross the level where this might qualify and that there would be a lot of associated science with that, that we could probably build a PhD program around. So, so we, did that. And so I basically started working on developing a ⁓ new type of SHG microscope that we can put on the body and get in vivo data. ⁓ I was new to the space. ended up sort of ultimately taking full responsibility of the entire project. So I had to learn optics, ⁓ everything from optics to image processing, the electronics and the signal generation and software and firmware. So basically built the whole system out and coming to it fresh took some liberties with the design and stuff that ⁓ were a little unconventional and ultimately made something that was extremely portable. and usable and we got some very exciting data we published in some nice journals and that was the seed because when I saw that ⁓ Paul Yoc was the chair of my PhD committee. I defended and I got my PhD and we started having an interesting conversation about like, this just useful as a science tool and muscle or is there broader applications? And I got introduced to Justin Coe in the dermatology department. talking about other things and because I had designed this sort of from the ground up and I kind of understood the entire landscape at a system and an architecture level, I realized we could adapt this for other tissues. then, so then I went into sort of a traditional bio design perspective from that point. I would say our, it was a little bit tech push because my goal was like, can we bring cellular level imaging into medicine, which we don't really have right now. ⁓ If that's the mission and that's the goal, then can we find in a disciplined way, can we find an application that's really a beachhead? So like a big market where there's a strong need or at least a potential latent need where it would justify investment and pushing in this direction. then we just continuously kind of moved towards oncology and the most common type of cancer is skin cancer. Skin cancers make up actually about 80 % of the... cancer diagnoses in the country. They're normally not included in the statistics because they're so numerous that they'll be an asterisk and they'll say with, you know, excluding skin cancers. And so we thought that was a market that made a lot of sense. ⁓ Skins on the outside of the body, we can image that completely non-invasively. And there's a lot of bottlenecks and pinch points in the dermatology workflow right now that are really difficult for that field. so that... moved in that direction and I decided I would, at that point I was an instructor at Stanford in bioengineering, but I decided to step out of academia, pursue this full time, had some patents, you know, and I went through the whole process, licensed the patents out of the university, raise some money, build a team, know, step, step, step. So it was, ⁓ but I would say it was born out of a scientific need for better data out of the body. And that's turned into a clinical need. speaker-0: It sounds like it was a real marriage between identifying a breakthrough in technology and innovation in terms of live cellular imaging, and then finding the application and kind of meeting in between. because you had essentially built the entire tech stack, you were able to modify the innovation for the application. So that's very interesting. I also think it's a profound insight to think about. how you approach the innovation maybe in an unconventional way because you weren't bound by sort of the standard way of thinking if you had grown up in the typical sciences of imaging. in a way that almost served you as an advantage, is that right? speaker-1: I would say for sure, know, ⁓ I was just watching, Dan Gelbart is a kind of ⁓ a historic innovator that I like to watch and stuff. He just had a wonderful interview where he was talking about kind of unconventional or impossible problems, you know, and he was talking about the threshold for impossibility was, said, well, you know, if it violates the laws of physics, that probably gets you into the realm where it's not possible. He's like, unless there's a loophole, which I think is interesting. And so he said, well, maybe you know, maybe under certain conditions or maybe under kind of limited applications where you can do certain things. And that was some of the benefit that I had from learning this across an entire system level and kind of understanding where we were going. I mean, there's a, so there's a reason why we image histology and maybe I'll take a quick step back. So, when we diagnose anything in medicine for the last 150 years, ultimate diagnosis comes from pathology from a biopsy. you, you, will harvest tissue out. even when we think of diagnostic imaging, like CT MRI, ultrasound, those are looking for, let's say like golf ball size tumors or quarter sized objects where we're like, that looks very atypical. you will ultimately still need to harvest some tissue out of that. There'll usually be a, a punch or a needle or something, or maybe it's during surgery while you're cleaning out the margins where you're going to need to get cellular level tissue. and we mount it on glass and we image it. And it's all because of optical limitations. So what we see in a visible spectrum where those wavelengths can only penetrate tens of microns into tissue. this is why you can't put your hand on a pathology microscope and you'll see nothing because it can't penetrate even through the tiniest little 10 micron layer of the outside of our skin. And there's no light from inside the skin, so there's nothing to come back, right? So historically, the only way to see these structures is we have to cut them out, slice them four microns thin, put them on glass, and back illuminate them with light. It's just physical optics, right? And so if you wanted to image this in the body, it seemingly would violate physics, unless you have a loophole. And the loophole is if you say, what if we don't use a single photon, one photon in, one photon out, if you use this two-photon approach where you're sending in You send in two lower energy photons, but they kind of combine their energy and then they emit light. The advantage of the lower energy photons are at longer wavelengths. They can penetrate much deeper into the skin. So you can actually, or tissue, you can actually get them hundreds of microns into the tissue and even to a sharp focus. They can combine and when they combine and cause this nonlinear effect, they emit light. The tissue becomes its own light source. And so the two photon or the multi-photon approach gives you a mechanism to get light deep into tissue and generate a signal back and then and Very importantly that signal that comes back is in a different color and it's molecularly specific So those are those are the two kind of key important ingredients of histopathology and this is why we the common stain is H &E Hematoccin and eosin it's an H &E slide because you need contrast and contrast so that you can see The different structures on the tissue if you if you just slice the tissue for microns then and look at it It'll look like an orange pill with no contrast. So you need cellular resolution and then you molecular contrast. And if you have those two ingredients, you basically have histology and multi-photon gives you an approach to do that. So that was like a loophole where you can introduce kind of a new physics and that gives you a way to image. Now from a medical perspective, it's very interesting. I think a lot of folks don't realize how few imaging modalities we actually have in medicine, you know, cause you see You see thousands and thousands of imaging products and you think that there's, there's a gajillion of them and now we have AI and so their imaging is abounds and it's everywhere. But, ⁓ what, when you really look at it, there's only maybe like half a dozen. So, you know, you've got, ⁓ X-ray, which is actually as old as, as histopathology. That's from the 1800s. You know, CT, which is fancy X-ray, ⁓ MRI, ultrasound, PET, and SPECT. Most of these technologies are in the range of 50 to 60 years old. They've been grandfathered in. ⁓ What you see as new technologies are variants of those, you so they're different deployments of that, but they use the same underlying physics, you know, the butterfly ultrasound device is using ultrasound, albeit with a kind of a new hardware deployment and, know, with some digital tools on top of that, but it's still sort of the same physics of like echolocation sort of. ⁓ What we introduced to through InSpektra, multi-photon has never been considered by the FDA. So when we got this device clear, we were introducing a completely new modality. we grew that field from let's say six or seven to eight. And that is a massive lift, we found out. It's ⁓ very hard to introduce a ⁓ brand new imaging modality in physics and to navigate that in a complicated regulatory pathway. ⁓ Maybe we'll talk about that, but that was. a whole journey, you know, but I am very proud to say that we did do that. And so we've grown this world of a handful of imaging modalities to a handful plus one. And I think that's a massive impact, you know, that I'm very proud of. speaker-0: No, it's very impressive, especially when you talk about live cellular imaging. I'm curious with this concept of identifying the loophole in physics and through an unconventional means, is part of the challenge that you run into skepticism. mean, essentially, if you've been looking at the same standard modalities for decades, and now you introduce essentially a loophole in terms of how people have been thinking of it, in this case with a multi-photon approach. Do you run into some level of skepticism in terms of its ability to actually image life cellular anatomy? speaker-1: Absolutely, and especially when the establishment of some of the best and the brightest have been trying it for a long time and haven't figured it out. ⁓ So, multi-photon as a field has been used actively in academia probably for about 30, 35 years. And from its first introduction, it didn't take a genius to realize that, this would be really useful for live tissue. The problem was there was a physical barrier of deploying the technology in a way that was clinically practical. You know, it's like the machines are too big, they're too cumbersome, they're too clunky. You can't get them to be, you know, robust enough and repeatable enough to use on live tissue. They can't shrink them. And then it takes like a PhD to operate, you know? So it was just like, just not practical, right? And so in the early, like what I had realized was by making this project to Image Muscle was I had actually solved several of these problems. ⁓ Some of them which were considered, you know, physics problems. Yeah, like laws of physics, like optical issues, ⁓ lenses image really well in a flat plane. So we'd call the XY plane. So when you line up to take a family photo, we all line up shoulder to shoulder. Everybody knows this. It's like you don't line up in single file because if you lined up single file, you couldn't see through the first person. That's one. And two, you couldn't even focus on the back person because you can only focus at one depth, But what you want to do in histology is exactly that. And especially in skin, it's a layered structure and you want to image through the depth. And that's not the way lenses normally work. ⁓ When you use them in that way, the performance drops drastically. It's well understood in the physics. And so you would basically say, you you probably can't get a crisp image that way unless you find a loophole, right? I had found a loophole for that. ⁓ So there's actually maybe three major loopholes in our technology which are really cool and we documented those in various degrees in our paper that we published in Nature Scientific Reports. So we had introduced the ability to shift the focus in 3D space without physical movement. That's one, because you want to be able to move up and down in the tissue. The second was a way to get a crisp cross-sectional image where lenses don't work well generally that way. And then the third, is on, it's a multimodal ⁓ device uses different types of microscopes. It's actually two microscopes in one. That other microscope, which is confocal, every single confocal in the world uses a pinhole, but we found a way to do it without a pinhole, and that has some tremendous advantages. ⁓ So there's like three sort of physics loopholes built into this system. It was hard to get faith in that early on, especially early on, know, we weren't really going necessarily entirely to VCs. We were raising money through, you know, grants, SBIR. type mechanisms and it was hard because those grants are read by panels of people that are experts in this space and they're like, this will never work. ⁓ like, I've tried it for 20 years. There's no way that you can have a free handheld multi-photon and touch it to skin and actually have that stable enough that you can generate a micron resolution image. Like that'll never be possible. so we got rejected, the first six grant applications that we applied got rejected. The first one's Brutally. ⁓ What happens at the end of the day, ultimately, is you got to prove it to people. So we just got really scrappy and found ways to cobble some of the technology together and basically start taking pictures. And eventually, through evidence, we're starting to convince people. then at tipping point, tipped completely the other way to where we started to get some of the best grant scores in that group. They actually use one of our grants as a template example for new companies that are applying. so I've seen that entire reversal where it's like, you're crazy and you're wrong and you don't know what's going on to like, ⁓ wow, like this is like the cutting edge and this is very creative. now, but it's evidence. So like ultimately, it's a prove me, prove it to me culture. speaker-0: Yeah, you can almost picture the standard kind of historical group standing behind a curtain and evaluating your proposal for multi-photon live cellular imaging, live tissue imaging, and them essentially saying this could never work. speaker-1: Yeah, they said in one grant they said this would be remarkable and they put it in quotes and it was like, it was like a kind of a veiled insult, right? Like that would just be remarkable, you know? And I was like, okay, I get it. But I was like, we'll come back, we'll come back, we'll show you something, you know, like, like to kind of prove it. yeah. speaker-0: Hopefully, you the letter. Have you kept the letter and thought about framing it somewhere? speaker-1: I move on. don't really dwell on the past too much. These are all, these are all valid and well-meaning people. I try to think about it from the perspective of, try to prevent myself from going down the same trap now as I meet other young innovators and they're working on new things. Don't dismiss like some of their ideas too quickly out of hand because you know, I've been on that side too, where I was like, no, I really think this will work. And people have been like, you're, this is bogus. I just want to try to make sure that grounded in science, but but open to new information and considering new evidence and new approaches, right? And kind of like ⁓ Dan Gilbert says, like, not violating physics, but creative kind of loopholes and interesting approaches, so. speaker-0: I'm curious if you found additional skepticism from VCs kind of in the post-bad blood publication era, you know, where there's a very obviously public kind of fall from grace within the diagnosis space doing something that was supposedly very innovative and groundbreaking. speaker-1: I remember at that time, some colleagues I have, you know, just throughout the field in illegitimate blood testing technologies, you know, that I really thought were grounded in real science. You know, they were like, they'd be like, we're going to run three tests, you know, or like it was more, you know, and use real blood from the vet. You know, it like very rational stuff, like things that were not really violating like what's feasible with real science. And they ran into a lot of problems because, you know, they would actually have to burn one or two slides in their deck to say, we're not. there or no. And as you know, like when you're giving a pitch and you're on a short timeline and like every slide and every word matters, that's expensive to have to try to differentiate yourself a little bit. So I do think there was some of that blowback. ⁓ But even under the best of scenarios, the VCs are very critical and very discerning. we still just go in there every single time with kind of the same approach. ⁓ We know what we have, we think it's good. We got evidence for that, you know, and we're just going to lay out the story. And it's mostly about finding fit more than anything. It's like, it's got to be a VC that understands our trajectory, our direction, our unique advantage and aligns with that. You know, and if they don't, they don't. speaker-0: And with evidence, the concept of a virtual biopsy, that just feels so powerful. Can you describe what some of the applications might be? And I mean, you've kind of started to describe the current workflow. So maybe start with what's the current workflow, for example, in a skin cancer detection, and how might a virtual biopsy transform that whole space? speaker-1: Yeah, so the way that everything in the, at least in the United States works is we'll have about 45 million visits to the dermatologist every year in the United States. They have to funnel through roughly 6,000 dermatology clinics. So you're funneling from 40, know, 45 million people into 6,000 clinics, three orders of magnitude. It's crowded. And this is why people will take... sometimes three, five months to get an appointment with your dermatologist. But the reason you do it is because ⁓ any clinical decision about your skincare in a medical sense has to be made off of a pathology-read biopsy. if ⁓ you're evaluating the potential risk of skin cancer and then the treatment for that skin cancer, it has to get physically biopsied. And that's just the standard of care guidances that we use. And what that means is that everybody, and most of these people don't have actually, bad conditions. So out of that 45 million, we might identify anywhere from six to eight million skin cancers every year. So most of them don't. And not everyone's going in just for skin cancer. They're going for other types of skin treatment. You know, it be pigmentary or inflammatory like eczema, rosacea. ⁓ But you're funneling a lot of people through a massive bottleneck. Anything that's suspicious of skin cancer gets biopsied, sent to the lab. Lab makes a slide. that gets red and then based on the outcome of that slide, you go through treatment. So of the 45 million, we biopsy about 15 million every year. Roughly half of those are negative, so nothing happens, but you do get cut and scarred in places that you care about, like it's usually your face. And then the other 8 million then get treated and split roughly evenly between a process called Mohs surgery, which is where they will dig out the cancer stage by stage to get to clean margins. That's typically in sensitive areas, particularly the face. ⁓ If you have a skin cancer on your back, they can do what's called a surgical excision. They basically just cut a large border around it and they have good evidence for the different varieties of skin cancer, how wide they have to go. So ⁓ the main skin cancer that people think of is melanoma. That's the one we hear about all the time. It's the most aggressive and most deadly. It's also the most rare of the mainstream cancers. It's only about one to 2 % of the skin cancer volume. 98 % of the skin cancers are basal cell carcinoma and squamous cell carcinoma. They tend to be a little slower growing, less likely to metastasize, ⁓ but much more abundant, and they make up the large volume of skin cancers. So, okay, so where do we fit in all of this? So, part of the problem is, I say it's like if the only way can get your mail was to go to the post office. Like, think of the traffic jam you would have. post office, right? Like there's a reason why, you know, things get delivered to our houses. We don't have to all physically go there and grab our envelopes. The idea would be, could you change that workflow so that you don't maybe all have to go like, huddle into this constriction? Could we maybe scan earlier, scan non-invasively, ⁓ proactively, and maybe just identify the people that actually have high risk of a condition? And it would be interesting to change that workflow from a see everybody where you're screening out a ton of people to just really focus on the folks that really have the risk of a condition. so that's the motivation behind the technology in that medical capacity. We've done a couple of clinical trials now. One of those was a pivotal for FDA clearance where we imaged patients that were getting biopsied anyway for suspicion of skin cancer, but we first imaged them with our device. And then we had the histology from the traditional slide so that we could do head-to-head direct comparison and evaluation. That paper was just recently published in JAMA dermatology, showed a very high correspondence between on a feature by feature level on histology, over 96%, ⁓ which is right on par with honestly traditional pathology. That's another important thing too, which is like, what is ground truth? We think of pathology as like a binary truth, but the reality it is evaluated by people. There have been studies where you'll have a pathologist read a slide and then six weeks later they'll read the same slide and they'll agree with themselves. It depends on the cancer. Like for skin cancer, they'll agree about 94 % of the time. So it's like, right? So, cause it's not perfect. ⁓ If you look at complex cancers, it's actually kind of scary things like lung and prostate is lower, maybe like 70 or 80 % where they'll produce the same sort of diagnosis because they're somewhat subjective and very complicated. So this is, that's the nuance in histopathology. That's always been our focus. Now, what I think is interesting and what's happened a little bit more recently is that skin as a field, dermatology is moving hard towards science and broadening its perspective to treat skin as an organ. I think we forget that sometimes. The skin is a physical organ. It's our largest organ. And it's the one organ that's exposed to ultraviolet and toxins. And it's intimately connected to health within the body. And what we're seeing is a broadening of this perspective. from medical all the way to beautiful. And in between you have sort of clinical, is like these non-threatening, non-life-threatening diseases. So they're not skin cancers, but maybe they're pigmentary or inflammatory conditions like vitiligo, melasma, ⁓ alopecia, rosacea, eczema, those sorts of psoriasis, those types of conditions. And then all the way towards aesthetics. because all of these things are... driven by an underlying cause of inflammation and photo damage. So if you can image tissue histology, turns out that there is this broader perspective now in skin that's very interesting. so part of running a company in this space, one, we want to have this impact. My deep mission is to try to bring the capacity of cellular imaging into the field of medicine and clinical practice. And part of it is also being nimble and responsive to the trends and the tides in the world. And what we're seeing is a strong, very strong pull for science into what's more traditionally aesthetic dermatology and cosmetics. And we've been approached by a lot of groups in this space that are developing more sophisticated therapies. They're kind of like biotech companies with interesting approaches that are actually affecting potentially the structure and composition of skin. And even some of those folks are even interested. in validating those claims and maybe even elevating these almost to like a medical treatment, like a drug or something, and pursuing regulatory pathways. And what's exciting about that is that's a little more of a cash pay, ⁓ hot market trend that we feel we can apply to. So part of us being a little nimble is pivoting in that direction to take advantage of that need and that pool. But it's all on the same platform. And so we see that as a way to drive some investment, to get some technology out there, build, keep building up our data sets and advancing our AI models, and then give us a foothold from which we can expand into all the other different little ⁓ corners of dermatology that we're very interested in. So, so we're seeing, we're seeing a trend like that right now, a big push towards regeneration and longevity of skin reprogramming. particularly mitochondrial activity to boost cell activity. And so one of the things we're building in our, we're building a next generation system right now. And part of what we're building into that is metabolic sensing. So this is a sort of a third modality off of that same platform where we would one, not just see structure and composition, but dynamic cell activity. And so then can you see, can the cells actually get boosted in their energy? Step one and then step two does that result in beneficial remodeling that's good for the skin health. And so we're constantly staying nimble and adapting to the trends and the pools of the market. speaker-0: Yeah, so there's an important thread there as a founder and CEO in terms of being dynamic and being able to pivot as markets direct you into certain ways and places. And it's fascinating that you've taken this space technology, focused on medical applications, migrated to clinical, and now look at even other applications like beauty. And it sounds like even general health with a focus on metabolic could definitely come into play. And that's fascinating. speaker-1: Absolutely. And still, like I said, I expect this to go beyond this though. I think in the same way ultrasound is used in all different applications, ⁓ CT, same thing, CT was developed originally for ophthalmology for the eye, now we use it intravascularly. ⁓ Multifoton has that potential to be used across the body. We know from the use in academia that this is very effective at imaging all kinds of different... you know, cancers and tissues, you know, whether that's breast, prostate, ⁓ you know, into the bladder, intraoperatively, surgical guidance of margins and most surgery, or even, you know, removal of different types of cancers, rapid bedside pathology. I see this as, it's a true modality. And, you know, this is the first embodiment of that. But one of the things that we did when we got this to the FDA is we created a brand new category of imaging, multi-photon, which... actually creates a pathway now for other technologies to come in. And so I wouldn't be surprised if in a decade or two we see variants of multi-photon. So it would be very exciting. speaker-0: And it strikes me that the application of AI to this platform could be very powerful. How are you thinking about data aggregation in terms of the ability to improve assessments over time? speaker-1: We've fortunately we've been very on top of the AI trend. The year that I got my PhD that I defended my PhD was the first year that AI ⁓ approach had won the ImageNet competition. That was in 2012 and that was sort of when it just all started to explode. ⁓ The way we've stayed in front of that trend has been through our data, really our data moat and designing our data in a forward way that it's extremely rich in what it encodes and that we can get the volume of data to be able to train these types of models. we, ⁓ one of the advantages of what we call this technology cross modal, having multiple modalities in there is when you take a photo with our device, it's actually taking four different photos simultaneously from different wavelengths and even from different physical optical mechanisms. And what that produces ⁓ is a three dimensional data set that's very rich in terms of identifying structure and molecular composition. been building models around that data architecture. So not just like using a camera, which would be red, green, blue RGB. We have kind of a multi-spectral approach, multi-modal approach, and we build off of that rich data set to use all the raw data possible to reach the conclusions that we want. so ⁓ we use the most cutting edge models, but honestly, we use them off the shelf. Our advantage is that we produce a data set. We produce the data and the, you know, like the way the legs feed the wolf, we make the data, the data feed, the model. Those models consequently are essentially proprietary because we have the world's only multi-photon and we have the world's only multi-photon data sets. And then we've built them, we've, we've co-mingled and built them together to, to maximize the insights that you can draw from these data sets. So, ⁓ that's been our approach to. to sort of stay on the forefront of the AI trend. We've built some exciting models already that automate some key biomarkers in skin where we're advancing those through some clinical studies now. We're planning to publish these things and to bring these into the market. And we even submitted some preliminary ⁓ work on this to the FDA through a breakthrough designation. So the idea on, we have a breakthrough designation for what would be our future AI assistive technologies, would ⁓ be a of a further step in streamlining this device. So one is just, you image non-invasively? Two is that we showed that actually the device is easy enough to operate that you don't need a clinician. can use the support staff can gather the data, but you still then now need a, you know, an expert in DERM path to read and interpret this. And ⁓ where it gets really exciting is then using some of these AI tools to streamline that interpretation and and support it in a way where now you can start to imagine having, you know, scanners in regionally very remote or rural areas where, you know, you have one dermatologist that services, you know, at 200 mile radius and everybody's driving in for three miles, but they can get scanned and then those scans can get streamlined, triaged and preinterpreted. And then you could even, but even remotely share those with, you know, the world's best expert at Memorial Sloan Kettering or something, you know, Mount Sinai, right? And so. That would fundamentally change the way that we access and process histopathology. So we're very proactive about thinking about the digital future. And for us, it's about data volume, data connectivity, so streaming off the devices, and then designing models to utilize the full dimensionality of our data sense. speaker-0: ⁓ What a beautiful arc it would be if the technology is able to be used in some of the remote areas of... speaker-1: That would be great. Absolutely. There's a lot of skin cancer in the Southwest and there is a lot of remote populations, you know, just throughout the state itself also in the, you know, the reservations and ⁓ some of this kind of like ranching and farming communities where there's just not a lot of access to medical technology. think it'd be very, I mean, this device actually can run on 12 volts DC. You could have it in a van. someday, you I think it'd be great. yeah, I have broad, you know, dreams for these. Absolutely. It would be really fun to drive it through the Southwest. speaker-0: Yeah, yeah, well, let's lean into that a little bit if you're to look ahead the ten years How do you think imaging like what you're developing it in spectra could reshape early detection and potentially intervention? speaker-1: I do think it's going to move scan. I do think it would move scanning into potentially different environments and fundamentally change that, ⁓ that overall workflow. Now we, ⁓ we would need to pair this with some other technologies. don't, we don't solve the entire workflow challenge. One of the problems with why everybody has to go to the dermatologist is they also get the skin check, you know, so, so you're going to the, the, dermatologist or experts at, at scanning your entire body and they can find the four or five things that really need to be looked at. And honestly, ⁓ people like on our own, when we see weird things in the mirror and we're like, ⁓ that looks abnormal and stuff, we're not as good as that as they are. And that's why you really do need to go in and see somebody that has that expertise. But there are companies working very aggressively on encoding those expertise into full body camera technologies to kind of pre-screen and identify say like lesions of interest. So imagine a future where you could have almost like scan centers, you know, we sort of have these, we're seeing this a little bit like with the Pronovo's and an MRI type scanning centers, but imagine if you could go to a, location where you can get assessed and you could stand in the booth and it could identify kind of photographically the lesions that look like they've changed or they look a little different or maybe are a little bit concerning step one. And then that funnels it down to a finite number of lesions that we can scan with inspector technology, because we're not going to scan the whole body microscopically. But maybe now there's like four five areas that really need to get scanned. Those get imaged microscopically. And now we actually have histologic data on a handful of lesions that are possibly concerning with AI tools to do the analysis. And you've changed the whole fundamental workflow. somebody could go in there and get scanned. almost immediately, right? And so you may divert some of that traffic, some of that 45 million people that's getting congested into the dermatology a little bit outside. So ideally screen out the folks that don't really need to go or end triage and fast track the ones that do. And so let the dermatologist focus on treating the medical conditions, right? And I think that that could be a really exciting future, whether that's in standalone scan centers, whether that's potentially in primary care, know, Walgreens, CVS. mean, there's a lot of challenges to make these things happen, but I think technologically, the technology would allow you to do that. So we would just have to be thoughtful about how to build this within the medical system and provide the evidence necessary to really be able to drive a different future workflow. But I do feel from, you know, all the work I've done in this space that there is motivation for new tools, both from the patient and even the clinician perspective. Because I don't know, if you go into a dermatology clinic, it's like Black Friday. It's crazy, like every day. It is hectic and I actually feel for those dermatologists because I've seen them and I just feel like they are heroically working. seeing a lot of people and doing the very best they can, but their tools are still mostly trapped in the late 1800s. And so I'd love to see that advance. So I think this can all be collaborative. I think I lift everybody up. ⁓ That takes some time. speaker-0: Yeah, and it always does, but there's clearly a need and you've been up for the challenge. It's really impressive how you've navigated this entire journey. So looking back, if you could give some advice to med tech innovators who are trying to bring transformative technologies to market, what would you tell them? What would your advice be? speaker-1: Part of my common advice is ⁓ to seize opportunities without overanalyzing or over planning. I do think sometimes, especially in the culture now, and I see this in my kids, I see it in where they go to school, but there's so much professionalism in this space now that there's this idea that you've got a trajectory and a vision of where you want to go. And it can almost paralyze you out of opportunities where... You're like, I want to be an AI innovator or I want to be a medical innovator or whatever it is. And you think that you have to take certain internships, certain courses, connections and opportunities to get there. And then if they don't directly line up, then people get kind of paralyzed and frozen. Just see if there's somebody who has energy that actively wants to pull you into an opportunity, like just take it and learn something new. Even if you learn that that's not a direction you want to go, make a connection, build your network, do some good work, build a reputation that's positive, and then use that as a stepping stone. And when you look back, I think you'll find that they connect like people say, those dots connect in reverse, but ⁓ don't overanalyze those opportunities. then related to that is I think that is making those personal connections are absolutely key because a lot of times when you get to ⁓ to a fork in the road or a roadblock where you're not sure how you're going to get over it. A lot of times it comes down to having a connection or somebody that can help you take that leap. Whether that's an introduction to an investor or it's a job recommendation or whatever that is, your network of people around you that have connections to opportunities and it will endorse you ⁓ can be absolutely critical. So I just say like, take whatever opportunities present themselves. Learn something new, meet a new person, make a good connection, and just keep going. Like, don't stop. speaker-0: Keep going and don't stop. And a of the, a lot of times you get pulled into something because someone sees something in you that you don't even see in yourself. speaker-1: Absolutely. Yeah, don't be your worst. Don't always be reflective. Try to be honest with yourself. That is important to you. We don't want to be dismissive of where we can improve or where we need to do some work, but don't be too harsh on yourself either. And sometimes people with that broader perspective can see something where you have some potential that you might not be aware of and just be open to that opportunity. ⁓ Generally, I have found that when you have somebody who's motivated, who has a lot of energy that wants to bring you into something, that's a really good place to go. And just follow those paths and ⁓ be a little flexible with what you want to do. speaker-0: And keep going. Don't stop. That's great encouragement. Yeah. From the guy who was traveling more than 60 miles in high school, right? speaker-1: Well start. Right. Yeah. Yeah. Absolutely. speaker-0: This was just a great conversation. Congratulations on all the success within Spectra. It's been quite the journey and we're very excited to continue to follow it and discover all the applications that you can come up with with multi-photon applications. speaker-1: I love the conversation, Amare. Honor to be here. Thanks a lot, as always. speaker-0: And thank you to all of you for joining us today on Powering the Future with Thin. If this conversation inspired you, follow the show and share it with your medtech community. I'm Omari Bachnait. Stay inspired and keep innovating.